Business · 17/11/2017Updated: 10/17/2026 · 1 min read

FDA Announces Draft Guidance for Expedited Review of Regenerative Medicine Therapies for Serious Conditions

Summary

The FDA is releasing a draft document outlining its expedited review process for regenerative medicine therapies aimed at treating serious or life-threatening diseases, with the goal of accelerating the development and approval of these treatments.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 10/5/2026

Federal Agencies Review Forms Under the Paperwork Reduction Act

The Paperwork Reduction Act is being reviewed by federal agencies to streamline and simplify the paperwork process, aiming to reduce bureaucratic burdens on the public.

Read summary →

Business · 9/16/2026

Food and Drug Administration Announces Proposed Collection of Information for Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Read summary →

Business · 9/16/2026

Medicare Program; Medicare Appeals; Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2027

The Medicare appeals process will adjust its amount in controversy threshold amounts for ALJ hearings and judicial review, effective January 1, 2027, with new thresholds of $200 for ALJ hearings and $2,000 for judicial review.

Read summary →

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →

Business · 9/14/2026

NIH Proposes Enhanced Biosafety Policy for Biohazard Research

The National Institutes of Health is seeking public input on a new, comprehensive biosafety policy aimed at strengthening oversight and keeping pace with evolving biohazard risks, with the goal of ensuring gold-standard science under gold-standard biosafety conditions.

Read summary →

Business · 10/9/2026

Center for Scientific Review Notice of Closed Meetings

The Center for Scientific Review has announced closed meetings for the following review groups: the Neurological Sciences A Study Section and the Neurological Sciences B Study Section.

Read summary →